Parechovirus: an important emerging infection in young infants

Britton, Philip N; Jones, Cheryl A; Macartney, Kristine; Cheng, Allen C

doi:10.5694/mja18.00149

ARTICLE
AUTHORS
REFERENCES

Topics

Infectious diseases

Pediatric medicine

Summary

Epidemics of human parechovirus (HPeV) causing disease in young children have occurred every 2 years in Australia since 2013. HPeV genotype 3 caused the epidemic from late 2017 to early 2018.
Most HPeV infections cause no or mild symptoms including gastroenteritis or influenza-like illness. Characteristically, young infants present with fever, irritability and on occasions a diffuse rash (“red, hot and angry” babies).
Severe disease can manifest as meningoencephalitis, seizures or sepsis-like presentations (including septic shock), or less common presentations including signs of surgical abdomen.
Testing for HPeV by specific molecular tests is indicated in children younger than 6 months of age with characteristic presentations without another confirmed diagnosis including febrile illnesses with other suggestive features (eg, rash, seizures), sepsis syndromes (including shock), and suspected meningoencephalitis (which may be detected by magnetic resonance imaging only).
There are no effective antiviral therapies. Treatment is primarily supportive, including management of complications.
Some infants with severe HPeV infection may have adverse neurodevelopment. Follow-up by a paediatrician is recommended.

1 University of Sydney, Sydney, NSW
2 The Children's Hospital at Westmead, Sydney, NSW
3 University of Melbourne, Melbourne, VIC
4 Melbourne Academic Centre for Health, Melbourne, VIC
5 National Centre for Immunisation Research and Surveillance, Sydney, NSW
6 Monash University, Melbourne, VIC

Correspondence: allen.cheng@monash.edu

Acknowledgements:

Allen Cheng and Philip Britton are supported by NHMRC Fellowship funding. We thank the PAEDS surveillance nurses and investigators and investigators on the Australian childhood encephalitis and related studies including Julia Clark, Nigel Crawford, Jim Buttery, Christopher Blyth, Joshua Francis, Brendan McMullan, Alison Kesson, Nicole Dinsmore, Alissa McMinn, Sonia Dougherty, Carolyn Finucane and Christine Heath.

Competing interests:

No relevant disclosures.

1. Zurynski YA, McRae JE, Quinn HE, et al. Paediatric Active Enhanced Disease Surveillance inaugural annual report, 2014. Commun Dis Intell Q Rep 2016; 40: E391-E400.
2. Hyypia T, Horsnell C, Maaronen M, et al. A distinct picornavirus group identified by sequence analysis. Proc Natl Acad Sci U S A 1992; 89: 8847-8851.
3. de Crom SC, Rossen JW, van Furth AM, Obihara CC. Enterovirus and parechovirus infection in children: a brief overview. Eur J Pediatr 2016; 175: 1023-1029.
4. Shakeel S, Dykeman EC, White SJ, et al. Genomic RNA folding mediates assembly of human parechovirus. Nat Commun 2017; 8: 5.
5. Olijve L, Jennings L, Walls T. Human parechovirus: an increasingly recognized cause of sepsis-like illness in young infants. Clin Microbiol Rev 2018; 31. doi: 10.1128/CMR.00047-17.
6. Cordey S, L’Huillier AG, Turin L, et al. Enterovirus and Parechovirus viraemia in young children presenting to the emergency room: unrecognised and frequent. J Clin Virol 2015; 68: 69-72.
7. Vollbach S, Muller A, Drexler JF, et al. Prevalence, type and concentration of human enterovirus and parechovirus in cerebrospinal fluid samples of pediatric patients over a 10-year period: a retrospective study. Virol J 2015; 12: 199.
8. Sano K, Hamada H, Hirose S, et al. Prevalence and characteristics of human parechovirus and enterovirus infections in febrile infants. Pediatr Int 2018; 60: 142-147.
9. de Jong EP, van den Beuken MGA, van Elzakker EPM, et al. Epidemiology of sepsis-like illness in young infants: major role of enterovirus and human parechovirus. Pediatr Infect Dis J 2018; 37: 113-118.
10. Ito M, Yamashita T, Tsuzuki H, et al. Isolation and identification of a novel human parechovirus. J Gen Virol 2004; 85(Pt 2): 391-398.
11. Cumming G, Khatami A, McMullan BJ, et al. Parechovirus genotype 3 outbreak among infants, New South Wales, Australia, 2013–2014. Emerg Infect Dis 2015; 21: 1144-1152.
12. Khatami A, McMullan BJ, Webber M, et al. Sepsis-like disease in infants due to human parechovirus type 3 during an outbreak in Australia. Clin Infect Dis 2015; 60: 228-236.
13. Harvala H, McLeish N, Kondracka J, et al. Comparison of human parechovirus and enterovirus detection frequencies in cerebrospinal fluid samples collected over a 5-year period in edinburgh: HPeV type 3 identified as the most common picornavirus type. J Med Virol 2011; 83: 889-896.
14. Britton PN, Dale RC, Nissen MD, et al. Parechovirus encephalitis and neurodevelopmental outcomes. Pediatrics 2016; 137: e20152848.
15. Britton PN, Khandaker G, Khatami A, et al. High prevalence of developmental concern amongst infants at 12 months following hospitalised parechovirus infection. J Paediatr Child Health 2018; 54: 289-295.
16. Nelson TM, Vuillermin P, Hodge J, et al. An outbreak of severe infections among Australian infants caused by a novel recombinant strain of human parechovirus type 3. Sci Rep 2017; 7: 44423.
17. Britton PN, Dale RC, Elliott E, et al. Pilot surveillance for childhood encephalitis in Australia using the Paediatric Active Enhanced Disease Surveillance (PAEDS) network. Epidemiol Infect 2016; 144: 2117-2127.
18. de Crom SC, Rossen JW, de Moor RA, et al. Prospective assessment of clinical symptoms associated with enterovirus and parechovirus genotypes in a multicenter study in Dutch children. J Clin Virol 2016; 77: 15-20.
19. Watanabe K, Hirokawa C, Tazawa T. Seropositivity and epidemiology of human parechovirus types 1, 3, and 6 in Japan. Epidemiol Infect 2016: doi:10.1017/S0950268816001795 [Epub ahead of print].
20. Pellegrinelli L, Bubba L, Galli C, et al. Epidemiology and molecular characterization of influenza viruses, human parechoviruses and enteroviruses in children up to 5 years with influenza-like illness in Northern Italy during seven consecutive winter seasons (2010-2017). J Gen Virol 2017; 98: 2699-2711.
21. Bergallo M, Galliano I, Montanari P, et al. Molecular detection of human parechovirus in under-five-year-old children with gastroenteritis. J Clin Virol 2016; 85: 17-21.
22. Harvala H, Robertson I, Chieochansin T, et al. Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples. J Infect Dis 2009; 199: 1753-1760.
23. Verboon-Maciolek MA, Groenendaal F, Hahn CD, et al. Human parechovirus causes encephalitis with white matter injury in neonates. Ann Neurol 2008; 64: 266-273.
24. Vergnano S, Kadambari S, Whalley K, et al. Characteristics and outcomes of human parechovirus infection in infants (2008-2012). Eur J Pediatr 2015; 174: 919-924.
25. Selvarangan R, Nzabi M, Selvaraju SB, et al. Human parechovirus 3 causing sepsis-like illness in children from midwestern United States. Pediatr Infect Dis J 2011; 30: 238-242.
26. Aizawa Y, Izumita R, Saitoh A. Human parechovirus type 3 infection: an emerging infection in neonates and young infants. J Infect Chemother 2017; 23: 419-426.
27. Braccio S, Kapetanstrataki M, Sharland M, Ladhani SN. Intensive care admissions for children with enterovirus and human parechovirus infections in the United Kingdom and the Republic of Ireland, 2010-2014. Pediatr Infect Dis J 2017; 36: 339-342.
28. Casas-Alba D, Martinez-Monseny A, Monfort L, et al. Extreme hyperferritinemia in dizygotic twins with human parechovirus-3 infection. Pediatr Infect Dis J 2016; 35: 1366-1368.
29. Bigelow AM, Scott JP, Hong JC, et al. Human parechovirus as a cause of isolated pediatric acute liver failure. Pediatrics 2016; 138. doi: 10.1542/peds.2016-0233.
30. van de Ven AA, Douma JW, Rademaker C, et al. Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia. Antivir Ther 2011; 16: 611-614.
31. Kong KL, Lau JSY, Goh SM, et al. Myocarditis caused by human parechovirus in adult. Emerg Infect Dis 2017; 23: 1571-1573.
32. Yamakawa T, Mizuta K, Kurokawa K, et al. Clinical characteristics of 17 adult patients with epidemic myalgia associated with human parechovirus type 3 infection. PloS ONE 2017; 57: 485-491.
33. McGregor T, Bu’Lock FA, Wiselka M, Tang JW. Human parechovirus infection as an undiagnosed cause of adult pericarditis. J Infect 2017; 75: 596-597.
34. Tanaka S, Kunishi Y. Severe human parechovirus type 3 infection in adults associated with gastroenteritis in their children. Infect Dis (Lond) 2017; 49: 772-774.
35. Shinomoto M, Kawasaki T, Sugahara T, et al. First report of human parechovirus type 3 infection in a pregnant woman. Int J Infect Dis 2017; 59: 22-24.
36. de Crom SC, Obihara CC, de Moor RA, et al. Prospective comparison of the detection rates of human enterovirus and parechovirus RT-qPCR and viral culture in different pediatric specimens. J Clin Virol 2013; 58: 449-454.
37. Wildenbeest JG, Harvala H, Pajkrt D, Wolthers KC. The need for treatment against human parechoviruses: how, why and when? Expert Rev Anti Infect Ther 2010; 8: 1417-1429.
38. Wildenbeest JG, Benschop KS, Bouma-de Jongh S, et al. Prolonged shedding of human parechovirus in feces of young children after symptomatic infection. Pediatr Infect Dis J 2016; 35: 580-583.
39. Nielsen NM, Midgley SE, Nielsen AC, et al. Severe human parechovirus infections in infants and the role of older siblings. Am J Epidemiol 2016; 183: 664-670.
40. Khandaker G, Jung J, Britton PN, et al. Long-term outcomes of infective encephalitis in children: a systematic review and meta-analysis. Dev Med Child Neurol 2016; 58: 1108-1115.
41. Britton PN, Blyth CC, Macartney K, et al. The spectrum and burden of influenza-associated neurological disease in children: combined encephalitis and influenza sentinel site surveillance from Australia, 2013-2015. Clin Infect Dis 2017; 65: 653-660.
42. Britton PN, Dale RC, Blyth CC, et al. Influenza-associated encephalitis/encephalopathy identified by the Australian Childhood Encephalitis Study 2013-2015. Pediatr Infect Dis J 2017; 36: 1021-1026.
43. Huang YP, Hsieh JY, Wu HS, Yang JY. Molecular and epidemiological study of human parechovirus infections in Taiwan, 2007-2012. J Microbiol Immunol Infect 2016; 49: 321-328.
44. Seo JH, Yeom JS, Youn HS, et al. Prevalence of human parechovirus and enterovirus in cerebrospinal fluid samples in children in Jinju, Korea. Korean J Pediatr 2015; 58: 102-107.
45. Chiang GPK, Chen Z, Chan MCW, et al. Clinical features and seasonality of parechovirus infection in an Asian subtropical city, Hong Kong. PLoS One 2017; 12: e0184533.
46. Abedi GR, Watson JT, Pham H, et al. Enterovirus and human parechovirus surveillance - United States, 2009-2013. MMWR Morb Mortal Wkly Rep 2015; 64: 940-943.
47. Itta KC, Ghargi KV, Kalal S, et al. First detection of human parechovirus infection with diarrhoea, India. Infect Dis (Lond) 2017; 49: 151-152.
48. Rahimi P, Naser HM, Siadat SD, et al. Genotyping of human parechoviruses in Iranian young children with aseptic meningitis and sepsis-like illness. J Neurovirol 2013; 19: 595-600.
49. Chuchaona W, Khamrin P, Yodmeeklin A, et al. Detection and characterization of a novel human parechovirus genotype in Thailand. Infect Genet Evol 2015; 31: 300-304.
50. Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370: 829-837.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Parechovirus: an important emerging infection in young infants

Topics

Summary

Author

Comment

Do you have any competing interests to declare? *